Latest From Alaric DeArment
Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.
While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.
Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.
An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.
The company now turns to its next-generation Huntington drug, WVE-003.